Wird geladen...
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
This phase 2, open-label, multicenter study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas. The primary end point was objective response rate (ORR). Key secondary end points included safety, corr...
Gespeichert in:
| Veröffentlicht in: | Blood |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4425442/ https://ncbi.nlm.nih.gov/pubmed/24652992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-542142 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|